Monte Rosa Therapeutics EV/EBITDA
The EV/EBITDA (Enterprise Value to EBITDA) of Monte Rosa Therapeutics (GLUE) as of Oct 19, 2026 is -18.33. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -12.26 — a change of 49.55% (lower).
Get this data via API
Financial Data API
EV/EBITDA
-18.33
YoY
49.55%
Last updated:
The Monte Rosa Therapeutics EV/EBITDA history
3 Years
10 Years
25 Years
Max
| YEAR | EV/EBITDA | YoY |
|---|---|---|
| -18.33 | +49.55% | |
| -12.26 | +54.91% | |
| -7.91 | -19.42% | |
| -9.82 | -29.86% | |
| -14.00 | -70.40% | |
| -47.29 | -72.23% | |
| -170.26 | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Monte Rosa Therapeutics Stock analysis
Frequently Asked Questions about Monte Rosa Therapeutics stock
EV/EBITDA (Enterprise Value to EBITDA) of Monte Rosa Therapeutics is -18.33 in 2025.
EV/EBITDA (Enterprise Value to EBITDA) of Monte Rosa Therapeutics changed from -12.26 to -18.33, representing a 49.55% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Monte Rosa Therapeutics since 2006 – with annual values, charts, and detailed analysis.
The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.
To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).
A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Monte Rosa Therapeutics with sector peers and the industry average to assess whether it is attractive.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Valuation — Monte Rosa Therapeutics
All Key Metrics — Monte Rosa Therapeutics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth